BioSpace News Archive

Business

Regeneron Misses Q1 Earnings on Lower-Than-Expected Eylea Sales

Regeneron Pharmaceuticals on Thursday reported $1.4 billion in sales of its blockbuster eye drug in the first quarter of 2024, falling short of Wall Street’s expectations of $1.86 billion.

May 2, 2024
·
2 min read
·
Kate Goodwin
Drug Development

Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy?

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could soon provide more-robust data about candidates’ efficacy and safety.

May 2, 2024
·
5 min read
·
Ben Hargreaves
Business

Moderna Walks Away from Potential $3B Gene Editing Deal with Metagenomi

Citing a strategic prioritization by Moderna, Metagenomi announced Wednesday that the partners have “mutually agreed” to terminate their gene editing agreement.

May 2, 2024
·
2 min read
·
Tristan Manalac
Business

BridgeBio Spins Out Oncology Company with $200M in Financing

The new company, BridgeBio Oncology Therapeutics, is looking to advance two KRAS inhibitors and a blocker of the interaction between the RAS and PI3K pathways.

May 2, 2024
·
2 min read
·
Tyler Patchen
Business

Novo’s Q1 Revenue Grows 24%, Raises Guidance as Wegovy Sales Surge

Novo Nordisk on Thursday reported a jump in first-quarter 2024 revenue, driven by a more than 100% increase in sales of weight-loss drug Wegovy and the strong performance of type 2 diabetes medication Ozempic.

May 2, 2024
·
2 min read
·
Tristan Manalac
Deals

Novartis Buys Mariana Oncology in $1B Acquisition, Bolsters Radiopharma Assets

The Swiss drugmaker is paying $1 billion and committing up to $750 million in milestones for Mariana Oncology’s preclinical cancer pipeline and clinical supply capabilities, the companies announced Thursday.

May 2, 2024
·
2 min read
·
Nick Paul Taylor
FDA

FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira

Boehringer Ingelheim on Wednesday won the FDA’s approval for a high-concentration and citrate-free version of its Humira biosimilar Cyltezo, targeting AbbVie’s blockbuster drug.

May 2, 2024
·
2 min read
·
Tristan Manalac
Business

Astellas Inks Second CAR-T Agreement with Poseida to Develop ‘Convertible’ Cancer Therapies

Astellas Pharma and Poseida Therapeutics have entered into a second CAR-T contract to develop novel and flexible allogeneic cell therapies in oncology.

May 2, 2024
·
2 min read
·
Tristan Manalac
Business

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2024 and provided an update on key corporate milestones.

May 2, 2024
·
15 min read
Business

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.

May 2, 2024
·
6 min read